Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Please provide your email address to receive an email when new articles are posted on . Gammagard Liquid is an immune globulin infusion (human) 10% solution. It is the only IV-based immunoglobulin ...

"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...

BHV-1300 reduced total IgG by up to 84% in a four-week Phase 1 study. The treatment was well-tolerated, with no serious adverse events reported. Get access to the leaderboards pointing to tomorrow’s ...

Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...

Immunoglobulin replacement therapy (IgRT) represents a pivotal intervention in managing secondary immunodeficiency, a complication arising from treatments or underlying conditions that impair the body ...

Some IVIG brands, like Gammagard, contain added sugar. This could cause your blood glucose to rise temporarily. But studies don’t show weight gain as a typical side effect of IVIG. Intravenous ...

Rebecca's daughter recovered from Kawasaki disease after prompt treatment with donated plasma.

Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to develop the first immune therapy eye drops to prevent the long-term effects ...